{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:59:27Z","timestamp":1792839567546,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005626","name":"Universit\u00e4t Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005626","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40261-022-01140-y","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T09:03:22Z","timestamp":1653037402000},"page":"465-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome"],"prefix":"10.1007","volume":"42","author":[{"given":"Selim","family":"Corbacioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Topaloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4:332\u201346.","journal-title":"J Clin Exp Hepatol"},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/14740338.2012.749855","volume":"12","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Corbacioglu S, Ho VT, Kernan NA, Lehmann L, Maguire C, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12:123\u201336.","journal-title":"Expert Opin Drug Saf"},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","volume":"2","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2:1495\u2013509.","journal-title":"Blood Adv"},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"102827","DOI":"10.1016\/j.transci.2020.102827","volume":"59","author":"N Soyer","year":"2020","unstructured":"Soyer N, Gunduz M, Tekgunduz E, Deveci B, Ozdogu H, Sahin HH, et al. Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of Turkish Hematology Research and Education Group (ThREG). Transfus Apher Sci. 2020;59:102827.","journal-title":"Transfus Apher Sci"},{"key":"1140_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255\u201367.","journal-title":"Ann Intern Med"},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","volume":"40","author":"DC Valla","year":"2016","unstructured":"Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40:378\u201385.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1140_CR9","unstructured":"Defitelio (defibrotide sodium) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 2016. https:\/\/pp.jazzpharma.com\/pi\/defitelio.en.USPI.pdf. Accessed 2 Apr 2019."},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","volume":"17","author":"A Falanga","year":"2003","unstructured":"Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17:1636\u201342.","journal-title":"Leukemia"},{"key":"1140_CR11","unstructured":"Defitelio (defibrotide sodium) [summary of product characteristics]. Villa Guardia, Italy: Genium SpA. 2018. https:\/\/www.ema.europa.eu\/documents\/product-information\/defitelio-epar-product-information_en.pdf. Accessed 2 Apr 2019."},{"key":"1140_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139.","journal-title":"Lancet"},{"key":"1140_CR13","unstructured":"Chalandon Y, Simonetta F, Dantin C, Koutsi A, Mamez AC, Beauverd Y, et al. Defibrotide shows efficacy in the prevention of sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic stem cell transplantation: a retrospective study on 237 patients. European Society for Blood and Marrow Transplantation (EBMT); 25\u201329 March 2017; Marseille."},{"key":"1140_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1399-0012.2012.01604.x","volume":"26","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang Y, Huang H. Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clin Transplant. 2012;26:511\u20139.","journal-title":"Clin Transplant"},{"key":"1140_CR15","first-page":"CD009311","volume":"27","author":"DK Cheuk","year":"2015","unstructured":"Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015;27:CD009311.","journal-title":"Cochrane Database Syst Rev"},{"key":"1140_CR16","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating defibrotide for the prevention of veno-occlusive disease [press release]. 2020. https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-stops-enrollment-in-phase-3-study-evaluating-defibrotide-for-the-prevention-of-veno-occlusive-disease-301049642.html. Accessed 9 Oct 2020."},{"key":"1140_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25:1271\u201380.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1140_CR18","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bbmt.2018.02.015","volume":"24","author":"A Picod","year":"2018","unstructured":"Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, et al. Defibrotide for sinusoidal obstruction syndrome\/veno-occlusive disease prophylaxis in high-risk adult patients: a single-center experience study. Biol Blood Marrow Transplant. 2018;24:1471\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778\u201383.","journal-title":"Transplantation"},{"key":"1140_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018;53:138\u201345.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR21","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S2352-3026(19)30201-7","volume":"7","author":"KM Mahadeo","year":"2020","unstructured":"Mahadeo KM, Bajwa R, Abdel-Azim H, Lehmann LE, Duncan C, Zantek N, et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020;7:e61\u201372.","journal-title":"Lancet Haematol."},{"key":"1140_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41409-020-00998-w","volume":"56","author":"D Ragoonanan","year":"2021","unstructured":"Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, et al. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transplant. 2021;56:175\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.17219\/acem\/115070","volume":"29","author":"Z Szmit","year":"2020","unstructured":"Szmit Z, Gorczynska E, Mielcarek-Siedziuk M, Ussowicz M, Owoc-Lempach J, Kalwak K. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: did the modified Seattle criteria fit the characteristics of pediatric population? Adv Clin Exp Med. 2020;29:339\u201344.","journal-title":"Adv Clin Exp Med."},{"key":"1140_CR24","unstructured":"Antmen B, Sasmaz I, Karagun B, Erkman H, Serbest M, Turksoy D. B317-Defibrotide prophylaxis and treatment of hepatic veno-occlusive disease after pediatric allogeneic hematopoietic stem cell transplantation. Presented at: 45th Annual Meeting of the European Society for Blood and Marrow Transplantation; 24\u201327 March 2019; Frankfurt."},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood.V116.21.3483.3483","volume":"116","author":"A Bonini","year":"2010","unstructured":"Bonini A, Imovilli A, Ghirarduzzi A, Silingardi M, Pilia A, Gugliotta L, et al. Defibrotide low-dose continuous infusion after allogeneic stem cell transplantation as prophylaxis for veno-occlusive disease of the liver. Blood. 2010;116:3483.","journal-title":"Blood"},{"key":"1140_CR26","first-page":"573","volume":"38","author":"A Bonnin","year":"2016","unstructured":"Bonnin A, Devaux C, Baylatry MT, Vekhoff A, Ruggeri A, Lapusan S, et al. PT014: Prophylaxis of sinusoidal obstruction syndrome after allogeneic stem cell transplantation in high-risk adult patients. Int J Clin Pharm. 2016;38:573\u20134.","journal-title":"Int J Clin Pharm"},{"key":"1140_CR27","first-page":"S212","volume":"50","author":"E Calore","year":"2015","unstructured":"Calore E, Rossin S, Pillon M, Tumino M, Mainardi C, Toffolutti T, et al. Veno occlusive disease of the liver after hematopoietic stem cell transplantation (HSCT) in pediatric patients: Padova experience. Bone Marrow Transplant. 2015;50:S212.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1365-2141.2009.07871.x","volume":"147","author":"B Cappelli","year":"2009","unstructured":"Cappelli B, Chiesa R, Evangelio C, Biffi A, Roccia T, Frugnoli I, et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous busulphan. Br J Haematol. 2009;147:554\u201360.","journal-title":"Br J Haematol"},{"key":"1140_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.bmt.1705485","volume":"38","author":"S Corbacioglu","year":"2006","unstructured":"Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006;38:547\u201353.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.bmt.1705696","volume":"40","author":"F Dignan","year":"2007","unstructured":"Dignan F, Gujral D, Ethell M, Evans S, Treleaven J, Morgan G, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant. 2007;40:79\u201382.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR31","unstructured":"Giglio F, Xue E, Lazzari L, Greco R, Clerici TD, Marktel S, et al. P170: Prophylaxis with defibrotide in adults at very high risk of veno-occlusive disease: results in 11 patients. Presented at: 45th Annual Meeting of the European Society for Blood and Marrow Transplantation; 24\u201327 March 2019; Frankfurt."},{"key":"1140_CR32","unstructured":"Gray JC, Marshall L, Qureshi A, Ridwan R, Sankpal S, Ethell M, et al. Defibrotide as prophylaxis for veno-occlusive disease in children undergoing allogenic and autologous stem cell transplantation. Bone Marrow Transplant. 2008:S298\u20139."},{"key":"1140_CR33","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood.V104.11.1139.1139","volume":"104","author":"J Hasenkamp","year":"2004","unstructured":"Hasenkamp J, Conradi I, Wulf G, Jung W, Truemper L, Glass B. Prevention of veno-occlusive disease in hematopoietic stem cell transplantation due to defibrotide prophylaxis. Blood. 2004;104:1139.","journal-title":"Blood"},{"key":"1140_CR34","unstructured":"Joshi R, Kerridge I, Grace S, et al. Prophylactic defibrotide for the prevention of hepatic veno-occlusive disease (VOD) in hematopoietic stem cell transplantation. Blood. 2002;2002:413A."},{"key":"1140_CR35","unstructured":"Kikuta A, Fukuda T, Ohashi K, Taniguchi S, Asano-Mori Y, Horibe K, et al. Defibrotide for treatment of hepatic veno-occlusive disease following hematopoietic stem cell transplantation: results from the Japanese prophylactic use, phase II, randomized trial. Presented at: 44th Annual Meeting of the EBMT; 18\u201321 March 2018; Lisbon."},{"key":"1140_CR36","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1182\/blood.V112.11.3275.3275","volume":"112","author":"G Milone","year":"2008","unstructured":"Milone G, Poidomani M, Coppoletta S, Mauro E, Marturano E, Crispi F, et al. Defibrotide in prevention of liver toxicity in patients at high risk of VOD after HSC transplantation. Blood. 2008;112:3275.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1140_CR37","first-page":"428","volume":"99","author":"G Milone","year":"2014","unstructured":"Milone G, Spina P, Berritta D, Parisi M, Leotta S, Cupri A, et al. Defibrotide as phophylaxis of liver toxicity during allogeneic HSC transplantation in acute leukemia patients. Haematologica. 2014;99(Suppl. 1):428.","journal-title":"Haematologica"},{"key":"1140_CR38","unstructured":"Mohty M, Bourhis JH, Faraci M, et al. Defibrotide prophylaxis for veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) after haematopoietic cell transplantation (HCT): analysis of a multicentre, multinational, prospective, observational registry study (EBMT PASS). Presented at: 47th Annual Meeting of the EBMT; 14\u201317 March 2021; virtual."},{"key":"1140_CR39","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1038\/bmt.2015.264","volume":"51","author":"C Pasqualini","year":"2016","unstructured":"Pasqualini C, Cros G, Dufour C, Abbou S, Dourthe M-E, Rigaud C, et al. Defibrotide prophylaxis of veno-occlusive disease in children with high-risk neuroblastoma treated with busulfan-melphalan high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2016;51:S260.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/pbc.21425","volume":"50","author":"A Qureshi","year":"2008","unstructured":"Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer. 2008;50:831\u20132.","journal-title":"Pediatr Blood Cancer"},{"key":"1140_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41409-020-01036-5","volume":"56","author":"YY Roh","year":"2020","unstructured":"Roh YY, Hahn SM, Kim HS, Ahn WK, Han JH, Kwon S, et al. Efficacy of low dose and short duration defibrotide prophylaxis for hepatic veno-occlusive disease after autologous haematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;56:411\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR42","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1182\/blood.V120.21.4508.4508","volume":"120","author":"E Tekgunduz","year":"2012","unstructured":"Tekgunduz E, Akpinar S, Bozdag SC, Tetik A, Kocubaba S, Cinarsoy M, et al. Effectiveness of defibrotide in the prevention of VOD among patients receiving allogeneic hematopoetic cell transplantation: a retrospective single center experience. Blood. 2012;120:4508.","journal-title":"Blood"},{"key":"1140_CR43","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1016\/j.bbmt.2017.12.292","volume":"24","author":"EN Wass","year":"2018","unstructured":"Wass EN, Lovejoy B, Glover N, Zhao Q, Sosa W, Chavan R. Prevention of veno-occlusive disease (VOD) with defibrotide in high-risk pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2018;24:S289.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01140-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:22:58Z","timestamp":1654946578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01140-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"16 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this study was provided by Jazz Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SC has consulted for and received honoraria from Gentium\/Jazz Pharmaceuticals. OT and SA have consulted for Jazz Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All of the data in this systematic review were taken from the published literature.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SC, OT and SA designed the meta-analysis. OT and SA performed the meta-analysis and analysed and verified the data. SC, OT and SA were involved in the interpretation of the data, and provided critical input, review and approval to submit the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}